SREBF1 and fatty liver disease: Mog V can improve the imbalance between lipid acquisition (de novo synthesis of lipids) and lipid clearance (lipolysis and fatty acid oxidation) by activating AMPK and subsequently exerting downstream regulation of SREBP1, PPAR-c and PPAR-α, thereby improving the liver steatosis induced by high fat diet in mice (Liu et al., 2019).